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The chemokine coreceptors play a significant role in HIV entry and pathogenesis. The V3 region of HIV envelope glycoprotein is
considered as a principal determinant for viral phenotype and tropism. The present study describes lack of association between the V3
genotype and viral phenotype of 18 Indian HIV-2 isolates. The viruses were isolated, confirmed by PCR and the HIV subtypes were
determined by sequencing V3 region of the env gene. The coreceptor usage and syncytium inducing (SI) capacity of isolates was determined.
Our study indicated that CCR5 coreceptor usage and NSI phenotype is predominant among Indian HIV-2 isolates obtained from patients in
the early stage of infection. Two of the four HIV-2 isolates obtained from the late stage patients were SI and dual tropic. Phylogenetic analysis
of these isolates revealed close relatedness to the isolates from western and southern India.
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The chemokine receptors play a significant role in HIV
cell tropism and pathogenesis (Philpott, 2003). HIV-1
subtype B-infected individuals in early and asymptomatic
stage mostly harbor non-syncytium inducing (NSI) and
CCR5 tropic (R5) viruses, while those in the late or
symptomatic stage harbor syncytium inducing (SI) and
CXCR4 (X4) or dual tropic (X4/R5) viruses (Connor et al.,
1997), demonstrating a switch in coreceptor usage during
disease progression (Connor et al., 1997). Such a coreceptor
switch was not observed in the HIV-1 subtype C infections
(Abebe et al., 1999; Cecilia et al., 2000; Peeters et al.,
1999). It was also demonstrated that the emergence of X4 or
X4/R5 and SI HIV-1 variants was a predictor of accelerated
disease progression (Hayman et al., 2004), rapid decline in0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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coreceptor usage (Hoffman and Doms, 1998).
In contrast to HIV-1, HIV-2 isolates were reported to use
a broad range of coreceptors irrespective of the disease
stage. It was demonstrated that a majority of the HIV-2
isolates like SIV used CCR1, CCR2b, CCR3, CCR8, BOB,
BONZO, CX3CR1, gpr1, APJ and US28 coreceptors in
addition to CXCR4 and CCR5 coreceptors (McKnight et al.,
1998; Morner et al., 1999). The X4 viruses isolated from
patients with late stage of HIV-2 infection indicate a similar
switch in coreceptor usage during HIV-2 disease progres-
sion (Morner et al., 1999; Sol et al., 1997).
The phenotypic switch has been associated with muta-
tions in the V3 region of gp120 envelope glycoprotein.
Sequence analysis of a large panel of V3 domains of SI and
NSI HIV-1 isolates has revealed that the occurrence of
positively charged amino acids at positions 11 and 25 are
associated with SI phenotype and also that the presence of
neutral or negatively charged residues are predictive of NSI
phenotype (De Jong et al., 1992; Fouchier et al., 1992).
Although the V3 region of HIV-2 envelope glycoprotein has005) 68 – 75
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1992), less is known about determinants of cell tropism
within this region. Studies by Albert et al. (1996) and
Morner et al. (1999) have found correlation between V3
genotype and biological phenotype, as measured by the net
charge, sequence heterogeneity and positively charged
amino acids at positions 9 and 10 in the V3 region of gp
105. Previous studies on most of the V3 sequences from
Indian HIV-2 isolates from western and southern part of
India have reported comparable amino acid sequences, but
the correlation of this with phenotypic characteristics and
coreceptor usage has not been studied (Grez et al., 1994;
Kannangai et al., 2003).
In spite of the ability to use a broad range of coreceptors
leading to increased cell range, HIV-2 is less pathogenic and
less transmissible than HIV-1 (Kanki et al., 1994; Marlink et
al., 1994). HIV-1 pathogenesis in context with coreceptors
has been studied in detail, but the significance of broad
coreceptor usage of HIV-2 in pathogenesis still remains
unclear. We report here an absence of correlation between
the genetic features of V3 region of gp 105 and viral
phenotype of the isolates from Indian HIV-2-positive
individuals.Results
Profile of HIV-2-positive individuals
Among the isolates obtained from the HIV-2 seropositive
individuals, 17 were from the state of Maharashtra and one
from the Gujarat state in the western region of India. The
mean age of participants was 34 years (range, 23–50 years),
15 were males and three were females. Twelve individualsTable 1
Phenotypic characteristics and V3 amino acid sequence of HIV-2 isolates
Isolate no. Disease stage
(CDC, 1993)
Coreceptor
usage
Syncytium
induction (MT2)
NARI-1 A1 R5 NSI
NARI-2 A1 R5 NSI
NARI-3 A2 R5 NSI
NARI-4 A2 R5 NSI
NARI-5 A2 R5 NSI
NARI-6 A2 R5 NSI
NARI-7 A2 R5 NSI
NARI-8 A2 R5 NSI
NARI-9 B2 R5 NSI
NARI-10 C1 R5 NSI
NARI-11 C2 R5 NSI
NARI-12 B3 X4/R5 SI
NARI-13 C3 X4/R5 SI
NARI-14 C3 R5 NSI
NARI-15 – R5 NSI
NARI-16 – R5 NSI
NARI-17 – R5 NSI
NARI-18 – R5 NSI
Disease staging of HIV-2-infected individuals and coreceptor usage, syncytium in
Indian HIV-2 isolates.had acquired infection through heterosexual route. One
individual had a history of multiple injections in clinical
settings. There was no reported risk factor for HIV infection
in five individuals.
Classification of the HIV-2-positive individuals
The absolute CD4 count could be determined in 14 out of
18 individuals. The median absolute CD4 count was 283
cells/mm3 (range, 78–830 cells/mm3). The individuals were
classified based on the clinical presentation and CD4 counts
as per CDC AIDS Surveillance case definition—1993
(CDC, 1992). The CDC categories A1, A2, B1 and B2
were classified as early HIV disease and A3, B3, C1, C2 and
C3 were classified as advanced HIV disease. Of 14
individuals, nine were in the early stage of the disease and
four in the late stage (Table 1). The median CD4 count of
individuals in the early stage of disease was 327 cells/mm3
(range, 227–755 cells/mm3) and that in the late stage was
95 cells/mm3 (range, 78–401 cells/mm3). In addition, one
individual presented with pulmonary tuberculosis but the
CD4 count of this individual was normal (830 cells/mm3).
In view of the normal CD4 count, this individual could not
be classified as having late stage HIV disease. The CD4
count was not available for four individuals of whom, two
were asymptomatic and two had pulmonary tuberculosis.
Coreceptor usage of HIV-2 isolates
The GHOST cells expressing CXCR4 or CCR5 core-
ceptors were used for determining coreceptor usage. Out of
18 HIV-2 isolates, nine isolates from patients in the early
stage of disease used CCR5 coreceptor, however, titres of
two isolates (Fig. 1, NARI-5 and NARI-7) were low. Two ofV3 sequence Net
charge
CKRPGNKTVVPITLMSGLVFHSQPINNRPRQAWC 34 6
CKRPGNRTVVPITLMSGLVFHSQPINTRPKQAWC 34 6
CKRPGNKTVVPITLMSGLIFHSQPINNRPKQAWC 34 6
CKRPGNRTVVPITLMSGLVFHSQPINTRPKQCWC 34 6
CKRPGNRTVVPITLMSGLVFHSQPINTRPKQC 32 6
CRRPGNKTVVPITLMSGLVFHSQPINDRPRQAWC 34 5
CRRPGNKTVVPITLMSGLVFHSQPINKRPKQAWC 34 7
CKRPGNKTVVPITLMSGLVFHSQPINKRPRQAWC 34 7
CKRPGNKTVVPITLMSGLVFHSQPINKRPRQAWC 34 7
CKRPGNKTVVPITLMSGLVFHSQPINERPRQAWC 34 5
CKRPGNKTVVPITLMSGLIFHSQPINTRPRQAWC 34 6
CKRPGNKTVLPITLMSGLVFHSQPINTRPRQAWC 34 6
CKRPGNKTVVPITLMSGLVFHSQPINKRPRQAWC 34 7
CKRPGNKTVVPITLMSGLIFHSQPINTRPRQAWC 34 6
CKRPGNKTVVAITLMSGLVFHSQPINARPRQAWC 34 6
CKRPGNKTVVPITLMSGLVFHSQPINKRPRQAWC 34 7
CKRPGNKTVVPITLMSGLVFHSQPINKRPRQAWC 34 7
CKRPGNKTVVPMTLMSGLIFHSQPINNRPRQAWC 34 6
duction, amino acid sequences and net charge of the V3 env region of 18
Fig. 1. Infection of GHOST-CXCR4/CCR5 cells with Indian HIV-2 isolates (NARI-1 to NARI-18) and standard positive controls (92/UG/029—CXCR4, 93/
UG/082—CCR5 and 93/BR/020—CXCR4/CCR5) from NIH AIDS Research and Reference Reagent Programme.
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tors and two used CCR5 coreceptor. In addition, one
individual who presented with pulmonary tuberculosis but
had normal CD4 count (830 cells/mm3) used CCR5
coreceptor. Isolates from four individuals for whom CD4
counts were not available used CCR5 coreceptor (Fig. 1,
Table 1).
Syncytium induction by HIV-2 isolates
The ability of HIV-2 isolates to induce syncytia was
assessed using MT2 cell line for assigning SI or NSI
phenotype. Nine isolates from patients in the early stage
were NSI. Two of the four isolates from patients in the late
stage of HIV disease were dual tropic (X4/R5) and induced
syncytia formation (as shown by presence of multinucleated
cells with increase in cell size) and two were NSI. In
addition, the virus from one individual who presented with
pulmonary tuberculosis but had normal CD4 count (830
cells/mm3) was NSI. The isolates from four individuals for
whom CD4 counts were not available were NSI (Table 1).
The ability of HIV-2 isolates to induce syncytia in other
cell lines like SupT1 and U-937 was also assessed. The
syncytium induction was more in SupT1 cell line compared
to MT-2 cells. Eight isolates induced syncytia in SupT1 cell
line while the remaining 10 were found to be NSI. There
was no correlation between the disease stage and syncytium
induction in SupT1 cell line. The isolates did not induce
syncytia in U-937 cell line (data not shown).
Subtype identification
The nucleotide sequences were analyzed on HIV Basic
Blast (www.hiv-web.lanl.gov) provided by Los Alamos
HIV database. The blast analysis of all 18 sequences
showed maximum homology with subtype A. The phylo-
genetic tree constructed using V3 sequences from repre-
sentative subtype A (U05359), subtype B (AF170058) and
subtype G (AF208027) further confirmed our isolates as
subtype A (Fig. 2). The tree also revealed maximumhomology of our sequences with sequences from western
India (U07104) and southern India (AY081795) as com-
pared to the sequences from eastern India (AY309063).
V3 sequence alignment
The consensus V3 region sequence for each of the
isolates was determined and aligned to HIV-2ROD reference
strain (M15390). The consensus sequences were compared
with other published Indian sequences from western,
southern and eastern India (Fig. 2).
Comparison of our HIV-2 isolates with HIV-2ROD
revealed mean percent homology of 83% (range, 80–
86%). The mean percent homology with isolates from
western India was 96% (range, 94–100%), with isolates
from southern Indian sequences was 95% (range, 93–99%)
and with an isolate from eastern India was 87% (range,
85–91%). The genetic distance was calculated by Kimura 2
parameter method (http://www.ebi.ac.uk/clustalw/). The
mean genetic distance of our HIV-2 isolates as compared
with isolates from western and southern India was 3%
(range, 0–6%) and with an isolate from eastern India was
13% (range, 9–16%).
In the V3 region sequences of Indian HIV-2 isolates, it
was observed that there was deletion of two amino acids (H
and Y) located at position 23 and 24 of HIV-2ROD sequence.
The amino acid (AA) residue K of HIV-2ROD at positions 2
and 7 was replaced by R in two and three isolates,
respectively. The AA residue K (at position 10) was
replaced by V in 17 isolates and by L in one isolate. In
17 isolates, the AA residue Q at position 11 was replaced by
P and by A in one isolate. Comparatively AA residues T and
L were found to be conserved in all 18 isolates, even though
they differed when compared with HIV-2ROD (M and H at
positions 13 and 18). The AA residue at positions 19 (V
replaced by I), 32 (R replaced by K) and 34 (A replaced by
C) also differed in four, five and in one isolate, respectively,
when compared with HIV-2ROD. The AA residue K (at
position 29) was replaced by N in three isolates, by each T
and K in six isolates and by A, D and E in one isolate each.
Fig. 2. Phylogenetic relationship of Indian HIV-2 isolates with representative isolates from subtype A (U05359), subtype B (AF170058), subtype G
(AF208027), HIV-2ROD (M15390), HIV-2RODX (X05291) and published Indian isolates from west (U07104), south (AY081795) and east (AY309063) India.
The tree was constructed by neighbour joining method using MEGA 2.1 software.
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33 were deleted in one isolate (Table 1, NARI-5).
Our study also demonstrated that CXCR4/CCR5 usage
and syncytium induction were not associated with sub-
stitution of positively charged amino acids at positions 9
and/or 10 in the V3 region (Table 1). No isolate had
positively charged amino acid residues at these positions.
The mean positive net charge was 6.2 (range, 5–7). There
was no difference between the mean positive net charge of
dual tropic and SI isolates (mean = 6.5, range, 5–7) and
CCR5 tropic and NSI isolates (mean = 6.2, range, 6–7). The
potential N-linked glycosylation site (amino acid positions
6–8) within V3 region was conserved in all our isolates.Discussion
HIV-2 epidemic is a public health problem in countries
like Portugal (Soriano et al., 2000., UNAIDS/WHO, 1998)
and Spain (Machuca et al., 1999), constituting 10–13% and
5% of all HIV infections, respectively. High prevalence of
HIV-2 (around 10% of all HIV infections) has been reportedin two rural communities of Senegal and New Guinea
Bissau of West Africa (Lagarde et al., 2003; Norrgren et al.,
1999) as well as in Angola and Mozambique (Schim van der
Loeff and Aaby, 1999). The highest prevalence of 28% has
also been reported among commercial sex workers in the
Gambia (Ghys et al., 1997; Langley et al., 1996). Although,
HIV-2 prevalence is low in other parts of the world, new
cases continue to be reported. Since the first report in the
year 1991 (Rubsamen-Waigman et al., 1991), HIV-2
infection has been reported from different regions of India
(Arora et al., 2004; Kannangai et al., 1999; Mukhopadhyay
et al., 2001; Rubsamen-Waigman et al., 1994).
As compared to HIV-1, HIV-2 infection is associated with
long clinical latency, slow disease progression, low viral load
and reduced transmission rate (Kanki et al., 1994; Marlink et
al., 1994). The HIV-1 pathogenicity has been found to be
associated with the genotypic and phenotypic characteristics
of virus, which could be related to variations in the V3 region
of gp 120 envelope protein (Hoffman and Doms, 1999;
McDonald et al., 2001). Some of these variations may result
in alteration of virological characteristics such as replication
kinetics, syncytium inducing capacity and cell tropism.
S. Kulkarni et al. / Virology 337 (2005) 68–7572Emergence of CXCR4 HIV-1 phenotypes is usually
associated with CD4 cell decline and faster disease pro-
gression (Philpott, 2003). Our study revealed that two of the
four isolates from individuals in late stage disease were dual
tropic and efficiently induced syncytia in MT2 cells. The
isolates obtained from individuals in the asymptomatic HIV
disease stage were CCR5 tropic and NSI. When individuals
were classified using WHO clinical staging system, 10
isolates obtained from HIV-2-infected individuals in clinical
stage 1 and clinical stage 2, utilized CCR5 coreceptor. In case
of the remaining eight isolates obtained from individuals in
clinical stage 3, two isolates utilized both CXCR4 and CCR5
coreceptors. These results are in agreement with the earlier
study by Morner et al. (1999) where seven isolates were
obtained from AIDS patients. One of these seven isolates
utilized X4 coreceptor, one used both X4/R5 and five utilized
R5 coreceptor. However, Sol et al. (1997) have studied
coreceptor tropism of seven isolates, which included two X4
isolates from AIDS patients and five R5 isolates from
asymptomatic individuals, indicating that isolates from AIDS
patients use X4 coreceptor only.
In this study, 16 of 18 HIV-2 isolates were R5 tropic. The
predominant use of CCR5 by HIV-2 is in agreement with
previous reports (Heredia et al., 1998; Morner et al., 1999)
but differs from other studies in which all HIV-2 isolates were
found to be CXCR4 tropic (McKnight et al., 1998). The fre-
quent use of CCR5 by Indian HIV-2 isolates could be
explained by several possible causes. Higher expression of
CCR5 in the Indian population, as reported earlier by
Ramalingam et al. (2002), may provide replication advantage
to R5 HIV strains over X4 HIV strains, explaining the lack of
shift in the viral phenotype during disease progression. Up-
regulation of CCR5 expression as a result of larger loads of
concomitant infections in developing countries like India
may result in continued selection of R5 strains. Mycobacte-
rium tuberculosis infection, which is the most common
opportunistic infection in India with 50–60% HIV-infected
persons developing tuberculosis, has been reported to cause
up-regulation of CCR5 (Fraziano et al., 1999; Morris et al.,
2001; Shalekoff et al., 2001). The frequent use of CCR5
could also be due to down-regulation of CXCR4 expression
due to circulation of activated T lymphocytes thereby affec-
ting propagation of CXCR4 strains (Bermejo et al., 1998).
The HIV-2, subtype A accounts for a majority of HIV-2
infections and is the predominant subtype in New Guinea
Bissau and Europe (Norrgren et al., 1997; Schim van der
Loeff and Aaby, 1999). Occurrence of subtype B has been
reported from eastern parts of West Africa (Ghana and Ivory
Coast) and occasionally from Europe (Schim van der Loeff
and Aaby, 1999). Although prevalence of HIV-2 (around
0.02%) is low in Sierra Leone, occurrence of subtype A,
subtype B, subtype E and subtype F has been reported from
this region revealing highest genetic diversity (Reeves and
Doms, 2002). Based on the sequence analysis of the V3
region, our studies revealed that globally distributed HIV-2
subtype A is the predominant strain in western part of India.The occurrence of HIV-2 subtype A has been reported
earlier from western India (Grez et al., 1994), southern India
(Kannangai et al., 2003) and eastern India (Bhanja et al.,
2004) in samples collected during the years 1991–1992,
1998–2001 and 2003, respectively. Comparison of the
percent homology (96% and 95%), mean genetic distance
(3%) and phylogenetic analysis revealed that our sequences
are closely related to the sequences of the isolates from
western and southern India, respectively. Less diversity in the
circulating HIV-2 from western India could be attributed to
low transmission rate of the virus and also due to introduction
of single genotype (subtype A).
Analysis of the V3 sequences revealed that there was no
association between the net charges and the syncytium
induction or coreceptor usage. It was also observed that the
amino acid residues at positions 9 and/or 10 (313 and/or 314
in the gp105 region) did not exhibit positive charge. The
consensus sequences were obtained from three clones from
each isolate. The amino acid residue F at position 20 was
replaced by S in two clones from an isolate. The amino acid
residues QAW, at positions 31–33, were replaced by PGM in
one clone obtained from one of the two X4/R5 isolates
(NARI-12). The amino acid residue H at position 21 replaced
by D in one clone from the second dual tropic isolate (NARI-
13). However, no replaced residue was positively charged
and hence did not increase the overall positive charge of the
V3 loop. Detailed analyses of the sequences obtained from
three clones from both dual tropic isolates revealed that none
of them had increased positive charge and truly represented
the sequences of dual tropic viruses. This is not in agreement
with the findings of Albert et al. (1996) and Morner et al.
(1999) who have reported correlation between the net charge
and the presence of positively charged amino acid at
positions 9 and 10 in the V3 region of HIV-2 and CXCR4
usage. Thus, charge on the amino acid residues at positions 9
and/or 10 may not be predictive of the SI phenotype or of the
CXCR4 coreceptor usage of the Indian HIV-2 isolates.
In summary, the present study indicated that R5 pheno-
type is the predominant phenotype among Indian HIV-2
isolates recovered from patients in the early stage. Two of the
four HIV-2 isolates obtained from late stage patients
exhibited shift from R5 to X4/R5. Our study revealed
predominance of globally distributed HIV-2 subtype A strain
in western part of India. The study also demonstrated lack of
association between the net charge, positively charged amino
acids in the V3 region of gp105 glycoprotein and the
syncytium induction or coreceptor usage.Materials and methods
Study subjects
After obtaining informed consent, relevant demographic
and clinical information was collected and blood sample
was drawn from 18 HIV-2-positive individuals residing in
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individuals were found positive for HIV-2 elsewhere and
were then referred to our clinic. The HIV-2-positive status of
these individuals was confirmed using ELISA as an initial
screening test (Labsystems HIV EIA, Finland and Detect
EIA, Canada). The positive samples were confirmed by a
rapid test (HIV Tridot, India) and Western blot (Cambridge
Biotech, Ireland and Innolia HIV Confirmation, Belgium).
Determination of HIV disease status
The patients were classified for HIV disease stage as per
CDC AIDS Surveillance case definition, 1993 (CDC,
1992) considering absolute CD4 counts and clinical
presentation. Using these criteria, 13 patients could be
classified for whom CD4 counts were available. In
addition, one individual who presented with pulmonary
tuberculosis but had normal CD4 count (830 cells/mm3)
could not be classified as having late stage HIV disease.
The remaining four patients were assessed for HIV related
symptoms. The CDC classification system was utilized for
data analysis.
The patients were also classified for disease stage using
WHO clinical staging system for HIV/AIDS (WHO, 2003),
since CD4 counts were not available for four individuals.
Determination of CD4 counts
The absolute CD4 cell counts were estimated on freshly
collected blood samples by two-color analysis using anti-
CD4 antibodies conjugated with phycoerythrin (Becton
Dickinson, San Jose, CA, USA). The results were analyzed
on a FACSort flow cytometer (Becton Dickinson, San Jose,
CA, USA). The absolute CD4 counts were calculated
utilizing the total leukocyte counts obtained by the manual
method using Neubaur’s chamber.
Virus isolation and virus stock development
The viruses from HIV-2-infected individuals were iso-
lated as described elsewhere (Kulkarni et al., 1999). Culture
supernates collected on 14th and 28th post infection (PI) day
were centrifuged and filtered through 0.22 A syringe filter
and stored at 70 -C. The culture supernates were used for
passaging the virus further (Passage 1) by infecting
activated heterologous normal lymphocytes for confirma-
tion of HIV-2 in culture using polymerase chain reaction
(PCR). The cultures were incubated for 14 days at 37 -C in
5% CO2 and humidified incubator. The cells and supernates
were collected on 7th and 14th PI day.
The Standard strains (92/UG/029, 93/UG/082, 93/BR/
020 and CMU02) were obtained from NIH AIDS Research
and Reference Reagent Programme. Stocks of these isolates
were prepared in PHA-P activated PBMCs from HIV
negative, heterologous donor and used as controls for
coreceptor determination and syncytium induction assays.Polymerase chain reaction
DNA was extracted from infected PBMCs collected on
7th and 14th PI day (Passage 1) using ISOQUICK Nucleic
acid Extraction kit (ORCA Research Laboratory Ltd., USA)
as per manufacturer’s instructions and stored at 20 -C until
further use. Amplification of 1.5 kb fragment of env gene of
HIV-2 was performed using nested PCR as described
elsewhere using primers derived from HIV-2ROD (Kulkarni
et al., 1999).
Cell lines
The GHOST cells (human osteosarcoma cells expressing
CD4 and CXCR4/CCR5 coreceptor along with green
fluorescent protein (GFP) as the reporter gene driven by
HIV-2 tat as a promoter) were obtained from Dr. Zolla-
Pazner, New York Veterans Affairs Medical Centre, NY,
USA. The cells were maintained in Dulbecco’s Modified
Eagles Medium (DMEM, Sigma, USA), containing 10%
FCS and 100 U/ml Penicillin, 100 Ag/ml Streptomycin, 500
Ag/ml Geneticin, 25 Ag/ml Hygromycin and 1 Ag/ml
Puromycin (Sigma, USA).
The T lymphoid cell lines—MT2 and SupT1, and U-937
(a macrophage cell line) used for determining syncytium
induction were obtained from NIH AIDS Research and
Reference Reagent Programme. The cell lines were main-
tained in RPMI containing 10% FCS and 100 U/ml
Penicillin, 100 Ag/ml Streptomycin, 80 Al/ml Gentamycin.
The cell lines were incubated at 37 -C in 5% CO2 and
humidified incubator.
Coreceptor usage using GHOST cells
GHOST cells expressing CXCR4 or CCR5 coreceptors
were used for determining coreceptor usage. The assay was
carried out as described by Cecilia et al. (2000). Briefly,
GHOST cells expressing CXCR4/CCR5 seeded at a con-
centration of 6x104 cells/well/0.5 ml medium in the 24-well
tissue culture plates, were allowed to grow for 24 h, when at
least 70% confluency was seen. The cells were infected in
duplicate with 1:2 diluted virus stocks in presence of 8 Ag/
ml DEAE-Dextran (Sigma, USA). After overnight infection,
the cells were washed, fed with the growth medium and
incubated for 3–4 days at 37 -C in 5% CO2 and humidified
incubator. The harvested cells were re-suspended in 1 mM
EDTA, fixed in 2% formaldehyde and analyzed by FACSort
flow cytometer (Becton Dickinson, San Jose, CA, USA).
The fixed cells were gated based on forward-scatter and
side-scatter. The number of infected cells was determined
using scattergram of fluorescence on the x axis versus
forward-scatter on the y axis after setting the gate with
uninfected cells. A total of 15,000 events were scored. The
mean number of fluorescent cells in the uninfected cell
cultures+3 SD was considered as the cut-off value, which
was 12+20 cells for GHOST-CXCR4 cells and 14+28 cells
S. Kulkarni et al. / Virology 337 (2005) 68–7574for GHOST-CCR5 cells. The cut-off value was determined
based on 20 observations in a total of five assays. Isolates
demonstrating number of fluorescent cells more than the cut
off value were considered as positive for virus infectivity
and coreceptor usage. Results were compared with the
standard strains 92/UG/029 (CXCR4), 93/UG/082 (CCR5)
and 93/BR/020 (CXCR4/CCR5) obtained from NIH AIDS
Research and Reference Reagent Programme.
Syncytium induction in T lymphoid cell lines
The MT2, SupT1 and U-937 cells were washed and
counted. 2  104 cells were seeded in each well of the flat
bottom, 96 well plates (Costar, USA). 50 Al of positive
culture supernate (passage 1) was added to the respective
wells in triplicate. The volume was adjusted to 200 Al/well
and the plates were incubated for 14 days at 37 -C in 5%
CO2 and humidified incubator. The cells were fed twice a
week with fresh medium and split once a week. The
syncytium induction was recorded microscopically on every
4th PI day. Standard strain CMU02, which induces
syncytium in MT2 and SupT1 cell lines, was included as
a positive control. The cytopathic effect (CPE) produced by
Indian isolates was compared with CPE produced by
CMU02 and then graded accordingly.
Cloning and sequencing
The amplified env gene was cloned into PCR2.1
(Invitrogen, USA) and PTZ57R/T (MBI Fermentas, Russia).
The clones were confirmed by restriction digestion follow-
ing kit manufacturer’s instructions and three clones were
obtained for each HIV-2 isolate. A 102-bp V3 region of
HIV-2 envelope gene was sequenced using H2-14 primer—
5V AGC CAT GCA GGA GGT GAA 3V. The fragments
generated were aligned using clustal W/1.8 software. The
alignment was utilized for construction of phylogenetic tree
using V3 sequences from representative subtype A
(U05359), subtype B (AF170058) and subtype G (AF
208027) and the MEGA 2 software (Kumar et al., 2001).
The V3 sequences for subtype C, subtype D, subtype E and
subtype F could not be obtained as these subtypes are
confirmed based on the sequences from either gag, pol or
gp41 regions of HIV-2 genome.Acknowledgments
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